Quarterly report pursuant to Section 13 or 15(d)

Noncontrolling Interest (Tables)

v3.21.1
Noncontrolling Interest (Tables)
 3 Months Ended
Mar. 31, 2021
Noncontrolling Interest [Abstract]  
Schedule of Noncontrolling Interest of Stockholders' Equity

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is with respect to the Company’s majority-owned subsidiaries Lucid Diagnostics Inc. and Solys Diagnostics Inc., summarized for the periods indicated as follows:

 

    Three Months Ended
March 31, 2021		     Year Ended
December 31, 2020		  
NCI - equity (deficit) - beginning of period   $ (2,369 )   $ (814 )
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise     —       5  
Net loss attributable to NCI - Lucid Diagnostics Inc.     (663 )     (1,503 )
Net loss attributable to NCI - Solys Diagnostics Inc.     (16 )     (109 )
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan     802       52  
NCI - equity (deficit) - end of period   $ (2,246 )   $ (2,369 )